Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
27-30 April, 2026
Not Confirmed
Not Confirmed
27-30 April, 2026
Bioprocess Internation...Bioprocess International Europe
Not Confirmed
Not Confirmed
27-30 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BPI Europe
Not Confirmed
Contact SupplierBPI Europe
Industry Trade Show
Not Confirmed
27-30 April, 2026
Industry Trade Show
Not Confirmed
27-30 April, 2026
Bioprocess Internation...Bioprocess International Europe
Industry Trade Show
Not Confirmed
27-30 April, 2026
Digital content
NEWS #PharmaBuzz
03 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/03/3267986/0/en/MiNK-Therapeutics-and-Memorial-Sloan-Kettering-to-Present-Phase-II-Study-of-agenT-797-Combination-in-PD-1-Refractory-Gastroesophageal-Cancer-at-AACR-2026.html
31 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/31/3265350/0/en/MiNK-Therapeutics-Reports-Q4-and-Full-Year-2025-Results-Phase-2-Programs-Advance-with-Impactful-Non-Dilutive-Momentum.html
17 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/17/3257040/0/en/MiNK-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlight-Platform-Expansion-Across-iNKT-Cell-Therapy-Programs.html
10 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/10/3252525/0/en/MiNK-Therapeutics-Announces-Collaboration-with-C-Further-to-Advance-PRAME-Targeted-iNKT-Cell-Therapy-for-Pediatric-Cancers.html
10 Mar 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-03-10/c-further-unveils-first-therapeutic-programmes-dedicated-to-paediatric-oncology
08 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/08/3215679/0/en/MiNK-Therapeutics-and-University-of-Wisconsin-Madison-Announce-Phase-1-Clinical-Trial-of-Allo-iNKT-Cell-Therapy-AgenT-797-to-Evaluate-Prevention-of-Graft-Versus-Host-Disease.html
Drugs in Development
Details:
The collaboration aims to develop a novel cell & gene therapy targeting PRAME for sarcoma treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: C-Further
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 10, 2026
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : C-Further
Deal Size : $1.1 million
Deal Type : Collaboration
Mink Therapeutics Teams Up with C-Further for Pediatric Cancer Therapy
Details : The collaboration aims to develop a novel cell & gene therapy targeting PRAME for sarcoma treatment.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
March 10, 2026
Details:
AgenT-797, a cell & gene therapy, shows promise in treating Graft-versus-host Disease (GVHD).
Lead Product(s): AgenT-797
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Cell & Gene Therapy
Sponsor: National Institute of Allergy and Infectious Diseases
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2026
Lead Product(s) : AgenT-797
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Mink, UW–Madison Begin Phase 1 Trial of Allo-iNKT Cell Therapy for Graft-Versus-Host Disease
Details : AgenT-797, a cell & gene therapy, shows promise in treating Graft-versus-host Disease (GVHD).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 08, 2026
Details:
MiNK-215, a cell & gene therapy targeting FAP-expressing CAF, shows promise in treating lung cancer.
Lead Product(s): MiNK-215
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 20, 2025
Lead Product(s) : MiNK-215
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mink Therapeutics Reveals MiNK-215's Strong Anti-Tumor Activity in Resistant Solid Tumors
Details : MiNK-215, a cell & gene therapy targeting FAP-expressing CAF, shows promise in treating lung cancer.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 20, 2025
Details:
The grant will support development of MiNK’s allo-iNKT cell therapy, AGENT-797, for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation.
Lead Product(s): AGENT-797
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: National Institute of Allergy and Infectious Diseases
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2025
Lead Product(s) : AGENT-797
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : National Institute of Allergy and Infectious Diseases
Deal Size : Undisclosed
Deal Type : Funding
MiNK Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy
Details : The grant will support development of MiNK’s allo-iNKT cell therapy, AGENT-797, for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
June 02, 2025
Details:
The collaboration will leverage Autonomous’ precision encRNA technology and MiNK’s innovative iNKT cell therapies, MiNK-215, an investigational, off-the-shelf cellular immunotherapy, and agenT-797.
Lead Product(s): MiNK-215
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Recipient: Autonomous Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 08, 2024
Lead Product(s) : MiNK-215
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Autonomous Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
MiNK And Autonomous Collaborate on Novel Therapies For Metastatic Tumors
Details : The collaboration will leverage Autonomous’ precision encRNA technology and MiNK’s innovative iNKT cell therapies, MiNK-215, an investigational, off-the-shelf cellular immunotherapy, and agenT-797.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 08, 2024
Details:
The net proceeds will advance the clinical development of MiNK-215, a novel cell therapeutic and allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein (FAP) in solid tumors.
Lead Product(s): MiNK-215
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: GKCC
Deal Size: $5.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 13, 2024
Lead Product(s) : MiNK-215
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : GKCC
Deal Size : $5.8 million
Deal Type : Private Placement
MiNK Therapeutics Announces $5.8 Million Private Placement and Board Observer Appointment
Details : The net proceeds will advance the clinical development of MiNK-215, a novel cell therapeutic and allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein (FAP) in solid tumors.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
May 13, 2024
Details:
MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in the preclinical stage as a novel approach for patients with colorectal cancer liver metastases.
Lead Product(s): MiNK-215
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2024
Lead Product(s) : MiNK-215
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MiNK Announces Preclinical Data Showcasing MiNK-215 Activity Against Colorectal Cancer
Details : MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in the preclinical stage as a novel approach for patients with colorectal cancer liver metastases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 06, 2024
Details:
AgenT-797 is composed of allogeneic iNKT cells being evaluated with botensilimab and balstilimab for gastroesophageal cancer treatment.
Lead Product(s): AgenT-797,Balstilimab,Botensilimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2024
First Gastric Cancer Patient Dosed in MiNK’s Phase 2 Trial
Details : AgenT-797 is composed of allogeneic iNKT cells being evaluated with botensilimab and balstilimab for gastroesophageal cancer treatment.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 14, 2024
Details:
MiNK-413, a next generation armored allogenic BCMA-CAR-iNKT product effectively eliminated MM cells in a CAR-dependent manner, without losing their T cell receptor (TCR)-mediated cytotoxic activity.
Lead Product(s): MiNK-413
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2022
Lead Product(s) : MiNK-413
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual...
Details : MiNK-413, a next generation armored allogenic BCMA-CAR-iNKT product effectively eliminated MM cells in a CAR-dependent manner, without losing their T cell receptor (TCR)-mediated cytotoxic activity.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 05, 2022
Details:
Clinical data show AgenT-797, an unmodified, allogeneic iNKT cell therapy can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity in Solid Tumor Cancers.
Lead Product(s): AgenT-797,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2022
MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers
Details : Clinical data show AgenT-797, an unmodified, allogeneic iNKT cell therapy can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity in Solid Tumor Cancers.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
